Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
The safety and immunogenicity profile of COVID-19 vaccines when administered concomitantly with seasonal influenza vaccines have not yet been reported. We therefore aimed to report the results of a substudy within a phase 3 UK trial, by evaluating the safety, immunogenicity, and efficacy of NVX-CoV2...
Saved in:
Published in | The lancet respiratory medicine Vol. 10; no. 2; p. 167 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.02.2022
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | The safety and immunogenicity profile of COVID-19 vaccines when administered concomitantly with seasonal influenza vaccines have not yet been reported. We therefore aimed to report the results of a substudy within a phase 3 UK trial, by evaluating the safety, immunogenicity, and efficacy of NVX-CoV2373 when co-administered with licensed seasonal influenza vaccines.
We did a planned exploratory substudy as part of the randomised, observer-blinded, placebo-controlled, phase 3 trial of the safety and efficacy of the COVID-19 vaccine (NVX-CoV2373) by co-administrating the influenza vaccine at four study hospitals in the UK. Approximately, the first 400 participants meeting the main study entry criteria-with no contraindications to influenza vaccination-were invited to join the substudy. Participants of the main study were randomly assigned (1:1) to receive two intramuscular injections of either NVX-CoV2373 (5 μg) or placebo (normal saline) 21 days apart; participants enrolled into the substudy were co-vaccinated with a single (0·5 mL) intramuscular, age-appropriate (quadrivalent influenza cell-based vaccine [Flucelvax Quadrivalent; Seqirus UK, Maidenhead] for those aged 18-64 years and adjuvanted trivalent influenza vaccine [Fluad; Seqirus UK, Maidenhead] for those ≥65 years), licensed, influenza vaccine on the opposite deltoid to that of the first study vaccine dose or placebo. The influenza vaccine was administered in an open-label manner and at the same time as the first study injection. Reactogenicity was evaluated via an electronic diary for 7 days after vaccination in addition to monitoring for unsolicited adverse events, medically attended adverse events, and serious adverse events. Immunogenicity was assessed with influenza haemagglutination inhibition and SARS-CoV-2 anti-spike protein IgG assays. Vaccine efficacy against PCR-confirmed, symptomatic COVID-19 was assessed in participants who were seronegative at baseline, received both doses of study vaccine or placebo, had no major protocol deviations affecting the primary endpoint, and had no confirmed cases of symptomatic COVID-19 from the first dose until 6 days after the second dose (per-protocol efficacy population). Immunogenicity was assessed in participants who received scheduled two doses of study vaccine, had a baseline sample and at least one post-vaccination sample, and had no major protocol violations before unmasking (per-protocol immunogenicity population). Reactogenicity was analysed in all participants who received at least one dose of NVX-CoV2373 or placebo and had data collected for reactogenicity events. Safety was analysed in all participants who received at least one dose of NVX-CoV2373 or placebo. Comparisons were made between participants of the substudy and the main study (who were not co-vaccinated for influenza). This study is registered with ClinicalTrials.gov, number NCT04583995.
Between Sept 28, 2020, and Nov 28, 2020, a total of 15 187 participants were randomised into the main phase 3 trial, of whom 15 139 received treatment (7569 received dose one of NVX-CoV2373 and 7570 received dose one of placebo). 431 participants were co-vaccinated with a seasonal influenza vaccine in the substudy (217 received NVX-CoV2373 plus the influenza vaccine and 214 received placebo plus the influenza vaccine). In general, the substudy participants were younger, more racially diverse, and had fewer comorbid conditions than those in the main study. Reactogenicity events were more common in the co-administration group than in the NVX-CoV2373 alone group: tenderness (113 [64·9%] of 174 vs 592 [53·3%] of 1111) or pain (69 [39·7%] vs 325 [29·3%]) at injection site, fatigue (48 [27·7%] vs 215 [19·4%]), and muscle pain (49 [28·3%] vs 237 [21·4%]). Incidences of unsolicited adverse events, treatment-related medically attended adverse events, and serious adverse events were low and balanced between the co-administration group and the NVX-CoV2373 alone group. No episodes of anaphylaxis or deaths were reported within the substudy. Co-administration resulted in no change to influenza vaccine immune response although a reduction in antibody responses to the NVX-CoV2373 vaccine was noted. NVX-CoV2373 vaccine efficacy in the substudy (ie, participants aged 18 to <65 years) was 87·5% (95% CI -0·2 to 98·4) and in the main study was 89·8% (95% CI 79·7-95·5).
To our knowledge, this substudy is the first to show the safety, immunogenicity, and efficacy profile of a COVID-19 vaccine when co-administered with seasonal influenza vaccines. Our results suggest concomitant vaccination might be a viable immunisation strategy.
Novavax. |
---|---|
AbstractList | The safety and immunogenicity profile of COVID-19 vaccines when administered concomitantly with seasonal influenza vaccines have not yet been reported. We therefore aimed to report the results of a substudy within a phase 3 UK trial, by evaluating the safety, immunogenicity, and efficacy of NVX-CoV2373 when co-administered with licensed seasonal influenza vaccines.
We did a planned exploratory substudy as part of the randomised, observer-blinded, placebo-controlled, phase 3 trial of the safety and efficacy of the COVID-19 vaccine (NVX-CoV2373) by co-administrating the influenza vaccine at four study hospitals in the UK. Approximately, the first 400 participants meeting the main study entry criteria-with no contraindications to influenza vaccination-were invited to join the substudy. Participants of the main study were randomly assigned (1:1) to receive two intramuscular injections of either NVX-CoV2373 (5 μg) or placebo (normal saline) 21 days apart; participants enrolled into the substudy were co-vaccinated with a single (0·5 mL) intramuscular, age-appropriate (quadrivalent influenza cell-based vaccine [Flucelvax Quadrivalent; Seqirus UK, Maidenhead] for those aged 18-64 years and adjuvanted trivalent influenza vaccine [Fluad; Seqirus UK, Maidenhead] for those ≥65 years), licensed, influenza vaccine on the opposite deltoid to that of the first study vaccine dose or placebo. The influenza vaccine was administered in an open-label manner and at the same time as the first study injection. Reactogenicity was evaluated via an electronic diary for 7 days after vaccination in addition to monitoring for unsolicited adverse events, medically attended adverse events, and serious adverse events. Immunogenicity was assessed with influenza haemagglutination inhibition and SARS-CoV-2 anti-spike protein IgG assays. Vaccine efficacy against PCR-confirmed, symptomatic COVID-19 was assessed in participants who were seronegative at baseline, received both doses of study vaccine or placebo, had no major protocol deviations affecting the primary endpoint, and had no confirmed cases of symptomatic COVID-19 from the first dose until 6 days after the second dose (per-protocol efficacy population). Immunogenicity was assessed in participants who received scheduled two doses of study vaccine, had a baseline sample and at least one post-vaccination sample, and had no major protocol violations before unmasking (per-protocol immunogenicity population). Reactogenicity was analysed in all participants who received at least one dose of NVX-CoV2373 or placebo and had data collected for reactogenicity events. Safety was analysed in all participants who received at least one dose of NVX-CoV2373 or placebo. Comparisons were made between participants of the substudy and the main study (who were not co-vaccinated for influenza). This study is registered with ClinicalTrials.gov, number NCT04583995.
Between Sept 28, 2020, and Nov 28, 2020, a total of 15 187 participants were randomised into the main phase 3 trial, of whom 15 139 received treatment (7569 received dose one of NVX-CoV2373 and 7570 received dose one of placebo). 431 participants were co-vaccinated with a seasonal influenza vaccine in the substudy (217 received NVX-CoV2373 plus the influenza vaccine and 214 received placebo plus the influenza vaccine). In general, the substudy participants were younger, more racially diverse, and had fewer comorbid conditions than those in the main study. Reactogenicity events were more common in the co-administration group than in the NVX-CoV2373 alone group: tenderness (113 [64·9%] of 174 vs 592 [53·3%] of 1111) or pain (69 [39·7%] vs 325 [29·3%]) at injection site, fatigue (48 [27·7%] vs 215 [19·4%]), and muscle pain (49 [28·3%] vs 237 [21·4%]). Incidences of unsolicited adverse events, treatment-related medically attended adverse events, and serious adverse events were low and balanced between the co-administration group and the NVX-CoV2373 alone group. No episodes of anaphylaxis or deaths were reported within the substudy. Co-administration resulted in no change to influenza vaccine immune response although a reduction in antibody responses to the NVX-CoV2373 vaccine was noted. NVX-CoV2373 vaccine efficacy in the substudy (ie, participants aged 18 to <65 years) was 87·5% (95% CI -0·2 to 98·4) and in the main study was 89·8% (95% CI 79·7-95·5).
To our knowledge, this substudy is the first to show the safety, immunogenicity, and efficacy profile of a COVID-19 vaccine when co-administered with seasonal influenza vaccines. Our results suggest concomitant vaccination might be a viable immunisation strategy.
Novavax. |
Author | Minassian, Angela M Goodman, Anna L Kumar, Lakshmi Rajaram, Sankarasubramanian Galloway, James Burns, Fiona Galiza, Eva Robertson, Andreana Dubovsky, Filip Plested, Joyce S Heath, Paul T Toback, Seth Glenn, Greg Swift, Pauline A Cho, Iksung Cosgrove, Catherine Graves-Jones, Alison Edelman, Jonathan Rivers, E Joy |
Author_xml | – sequence: 1 givenname: Seth surname: Toback fullname: Toback, Seth organization: Novavax, Gaithersburg, MD, USA – sequence: 2 givenname: Eva surname: Galiza fullname: Galiza, Eva organization: Vaccine Institute, St George's University of London and St George's University Hospitals NHS Foundation Trust, London, UK – sequence: 3 givenname: Catherine surname: Cosgrove fullname: Cosgrove, Catherine organization: Vaccine Institute, St George's University of London and St George's University Hospitals NHS Foundation Trust, London, UK – sequence: 4 givenname: James surname: Galloway fullname: Galloway, James organization: Centre for Rheumatic Disease, King's College London, London, UK – sequence: 5 givenname: Anna L surname: Goodman fullname: Goodman, Anna L organization: Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK; MRC Clinical Trials Unit, University College London, London, UK – sequence: 6 givenname: Pauline A surname: Swift fullname: Swift, Pauline A organization: Department of Nephrology, Epsom and St Helier University Hospitals NHS Trust, London, UK – sequence: 7 givenname: Sankarasubramanian surname: Rajaram fullname: Rajaram, Sankarasubramanian organization: Seqirus UK, Maidenhead, UK – sequence: 8 givenname: Alison surname: Graves-Jones fullname: Graves-Jones, Alison organization: Seqirus Australia, Melbourne, VIC, Australia – sequence: 9 givenname: Jonathan surname: Edelman fullname: Edelman, Jonathan organization: Seqirus USA, Summit, NJ, USA – sequence: 10 givenname: Fiona surname: Burns fullname: Burns, Fiona organization: Institute for Global Health, University College London, London, UK; Royal Free London NHS Foundation Trust, London, UK – sequence: 11 givenname: Angela M surname: Minassian fullname: Minassian, Angela M organization: Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, UK; NIHR Oxford Health Biomedical Research Centre, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK – sequence: 12 givenname: Iksung surname: Cho fullname: Cho, Iksung organization: Novavax, Gaithersburg, MD, USA – sequence: 13 givenname: Lakshmi surname: Kumar fullname: Kumar, Lakshmi organization: Novavax, Gaithersburg, MD, USA – sequence: 14 givenname: Joyce S surname: Plested fullname: Plested, Joyce S organization: Novavax, Gaithersburg, MD, USA – sequence: 15 givenname: E Joy surname: Rivers fullname: Rivers, E Joy organization: Novavax, Gaithersburg, MD, USA – sequence: 16 givenname: Andreana surname: Robertson fullname: Robertson, Andreana organization: Novavax, Gaithersburg, MD, USA – sequence: 17 givenname: Filip surname: Dubovsky fullname: Dubovsky, Filip organization: Novavax, Gaithersburg, MD, USA – sequence: 18 givenname: Greg surname: Glenn fullname: Glenn, Greg organization: Novavax, Gaithersburg, MD, USA – sequence: 19 givenname: Paul T surname: Heath fullname: Heath, Paul T email: pheath@sgul.ac.uk organization: Vaccine Institute, St George's University of London and St George's University Hospitals NHS Foundation Trust, London, UK. Electronic address: pheath@sgul.ac.uk |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34800364$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kMtOHDEQRS1EFB7hExJ5CRJO_Bp7ml00CQ8JhQXJKDtUtquDI7c9srshkx_N7zCQoTZXdaS6t3QPyG4uGQl5L_hHwYX5dCulUEwazo-lOOFc847pHbK_xaLbI0et_eabmc-15Pot2VN6zrkyep_8u4Uex_UpjcMw5fILc_TxeYccKPZ99ODXtPQU6OJmefWFiY4-gPcxIz3-tvzJFmUplVUn1BcGYYg5thErBvoYx3vaEFrJkGjMfZow_4XX63a2iaD4Z5VKhbHUNW2Ta-MUtml180AZYsNwSotrWB-wMpdiDs9klcCjK8yXPNaS0gu7h4ZU0bFGSO_Imx5Sw6OtHpIf51-_Ly7Z9c3F1eLzNfPa2JFZ7ECg4T70Myed5TAL1mlnlLMhWG9RCSOk6sx8U4ZU2lknDHb9TCg0TstD8uG_72pyA4a7VY0D1PXda8PyCWm4ggw |
CitedBy_id | crossref_primary_10_1016_j_lanepe_2023_100644 crossref_primary_10_1080_21645515_2023_2287282 crossref_primary_10_1016_j_cmi_2023_02_003 crossref_primary_10_1002_advs_202206095 crossref_primary_10_3389_fimmu_2023_1259399 crossref_primary_10_54724_lc_2022_e4 crossref_primary_10_1016_j_jtct_2022_10_010 crossref_primary_10_3390_vaccines11071213 crossref_primary_10_3390_jcm12134517 crossref_primary_10_1080_21645515_2024_2330770 crossref_primary_10_1080_21645515_2024_2317439 crossref_primary_10_3390_vaccines11010109 crossref_primary_10_1016_j_cmi_2022_12_008 crossref_primary_10_1080_21645515_2022_2131166 crossref_primary_10_1080_14760584_2024_2346589 crossref_primary_10_3390_ph15030322 crossref_primary_10_1001_jamanetworkopen_2022_8873 crossref_primary_10_1001_jamanetworkopen_2023_32813 crossref_primary_10_1016_j_ebiom_2024_105103 crossref_primary_10_1080_21645515_2022_2094653 crossref_primary_10_1016_j_amepre_2024_02_013 crossref_primary_10_1080_14760584_2024_2348608 crossref_primary_10_1080_21645515_2023_2275464 crossref_primary_10_3390_vaccines10091449 crossref_primary_10_1016_j_vaccine_2023_07_040 crossref_primary_10_1016_j_vaccine_2022_07_021 crossref_primary_10_1016_j_vaccine_2023_07_043 crossref_primary_10_1080_14760584_2023_2218913 crossref_primary_10_3390_vaccines12030312 crossref_primary_10_1371_journal_pone_0281812 crossref_primary_10_1016_j_vaccine_2023_06_042 crossref_primary_10_1080_21645515_2024_2327229 crossref_primary_10_1126_sciadv_abo4100 crossref_primary_10_3389_fbioe_2022_1052436 crossref_primary_10_1038_s41598_023_31818_y crossref_primary_10_3390_vaccines11010016 crossref_primary_10_1186_s43141_023_00574_x crossref_primary_10_1136_bmjmed_2021_000040 crossref_primary_10_1080_08964289_2022_2119361 crossref_primary_10_1016_j_lanepe_2023_100628 crossref_primary_10_1093_cid_ciad361 crossref_primary_10_1093_intimm_dxac031 crossref_primary_10_1016_j_vaccine_2023_11_057 crossref_primary_10_3390_vaccines12040420 crossref_primary_10_1007_s40121_023_00863_5 crossref_primary_10_1183_13993003_01390_2022 crossref_primary_10_1001_jamanetworkopen_2023_42151 crossref_primary_10_3390_vaccines12050514 crossref_primary_10_1021_acs_bioconjchem_3c00103 crossref_primary_10_3389_fimmu_2023_1248630 crossref_primary_10_1080_21645515_2024_2327736 crossref_primary_10_1007_s40261_022_01191_1 crossref_primary_10_1016_j_phrs_2023_106699 crossref_primary_10_1038_s41598_024_54421_1 crossref_primary_10_3390_toxins15090563 crossref_primary_10_1371_journal_pgph_0001053 crossref_primary_10_3390_vaccines10101751 crossref_primary_10_3390_vaccines11101624 crossref_primary_10_1016_j_cmi_2024_01_010 crossref_primary_10_3390_cells12091243 crossref_primary_10_3390_v14061126 crossref_primary_10_1007_s40615_022_01434_z crossref_primary_10_1016_j_vaccine_2023_09_013 crossref_primary_10_1360_TB_2023_1054 crossref_primary_10_3389_fimmu_2023_1167214 crossref_primary_10_3390_vaccines10060944 crossref_primary_10_1016_j_drudis_2022_08_004 crossref_primary_10_3390_jpm12020139 |
ContentType | Journal Article |
Contributor | Lawrence, Heather Pretswell, Carol H Vilimiene, Neringa Kara, Naveed Sowole, Lucy Smith, Katharine A Immanuel, Anita Grundy, Lynne Mann, Sandra Fok, Henry McKeon, Sean Miller, Karen Floyd, Hilary McFarland, Margaret Broadhead, Samantha Brown, Ellen Smith, Richard Edwards, Carole Rajeswaran, Thurkka Mohan, Mahalakshmi Davis, Jessica Fielding, Kirsty Sparrow, Geoff Jayatilleke, Thilina Hayre, Rachel Goddard, Suzanne Meyrick, Agnieszka Mathew, Moncy Valentine, Ruth Scicluna, Chiara Pandaan, Alice Nicol, Amy Bisnauthsing, Karen Smith, Karen Longshaw, Laura Townsend-Rose, Anna Movahedi, Roya Cinardo, Paola Edwards, Paul Milinkovic, Ana Rowbotham, Bridie Iyengar, Shalini Broad, Katharine Lucy Trottier, Lauren Richards, Nick Housman, Rosalie Byrne, Ruth Hamblin, Mike Osanlou, Orod Regan, Karen Norris, Karen English, Beverley Attenburrow, Mary-Jane Elliot-Garwood, Alison Mazzella, Andrea Price, Helen Boffito, Marta Bremner, Laura Munsoor, Imrozia Camilleri, Brian Cipriani, Andrea Soiza, Roy L Henshall, Catherine Shenoy, Anil Wright, John Cooney, Enya Morsell |
Contributor_xml | – sequence: 1 givenname: Roy L surname: Soiza fullname: Soiza, Roy L – sequence: 2 givenname: Robin surname: Brittain-Long fullname: Brittain-Long, Robin – sequence: 3 givenname: Chiara surname: Scicluna fullname: Scicluna, Chiara – sequence: 4 givenname: Carole surname: Edwards fullname: Edwards, Carole – sequence: 5 givenname: Lynn surname: Mackay fullname: Mackay, Lynn – sequence: 6 givenname: Mariella surname: D'Allesandro fullname: D'Allesandro, Mariella – sequence: 7 givenname: Amy surname: Nicol fullname: Nicol, Amy – sequence: 8 givenname: Karen surname: Norris fullname: Norris, Karen – sequence: 9 givenname: Sandra surname: Mann fullname: Mann, Sandra – sequence: 10 givenname: Heather surname: Lawrence fullname: Lawrence, Heather – sequence: 11 givenname: Ruth surname: Valentine fullname: Valentine, Ruth – sequence: 12 givenname: Marianne Elizabeth surname: Viljoen fullname: Viljoen, Marianne Elizabeth – sequence: 13 givenname: Carol H surname: Pretswell fullname: Pretswell, Carol H – sequence: 14 givenname: Helen surname: Nicholls fullname: Nicholls, Helen – sequence: 15 givenname: Imrozia surname: Munsoor fullname: Munsoor, Imrozia – sequence: 16 givenname: Agnieszka surname: Meyrick fullname: Meyrick, Agnieszka – sequence: 17 givenname: Christina surname: Kyriakidou fullname: Kyriakidou, Christina – sequence: 18 givenname: Shalini surname: Iyengar fullname: Iyengar, Shalini – sequence: 19 givenname: Arham surname: Jamal fullname: Jamal, Arham – sequence: 20 givenname: Nick surname: Richards fullname: Richards, Nick – sequence: 21 givenname: Helen surname: Price fullname: Price, Helen – sequence: 22 givenname: Bridie surname: Rowbotham fullname: Rowbotham, Bridie – sequence: 23 givenname: Danielle surname: Bird fullname: Bird, Danielle – sequence: 24 givenname: Karen surname: Smith fullname: Smith, Karen – sequence: 25 givenname: Olga surname: Littler fullname: Littler, Olga – sequence: 26 givenname: Kirsty surname: Fielding fullname: Fielding, Kirsty – sequence: 27 givenname: Anna surname: Townsend-Rose fullname: Townsend-Rose, Anna – sequence: 28 givenname: Karen surname: Miller fullname: Miller, Karen – sequence: 29 givenname: Jessica surname: Davis fullname: Davis, Jessica – sequence: 30 givenname: Alison surname: Elliot-Garwood fullname: Elliot-Garwood, Alison – sequence: 31 givenname: Lauren surname: Trottier fullname: Trottier, Lauren – sequence: 32 givenname: Paul surname: Edwards fullname: Edwards, Paul – sequence: 33 givenname: Margaret surname: McFarland fullname: McFarland, Margaret – sequence: 34 givenname: Orod surname: Osanlou fullname: Osanlou, Orod – sequence: 35 givenname: Laura surname: Longshaw fullname: Longshaw, Laura – sequence: 36 givenname: Jane surname: Stockport fullname: Stockport, Jane – sequence: 37 givenname: Lynne surname: Grundy fullname: Grundy, Lynne – sequence: 38 givenname: Katharine Lucy surname: Broad fullname: Broad, Katharine Lucy – sequence: 39 givenname: Karen surname: Regan fullname: Regan, Karen – sequence: 40 givenname: Kim surname: Storton fullname: Storton, Kim – sequence: 41 givenname: Declan surname: Ryan-Wakeling fullname: Ryan-Wakeling, Declan – sequence: 42 givenname: Brad surname: Wilson fullname: Wilson, Brad – sequence: 43 givenname: Malathy surname: Munisamy fullname: Munisamy, Malathy – sequence: 44 givenname: John surname: Wright fullname: Wright, John – sequence: 45 givenname: Anil surname: Shenoy fullname: Shenoy, Anil – sequence: 46 givenname: Beverley surname: English fullname: English, Beverley – sequence: 47 givenname: Lucy surname: Brear fullname: Brear, Lucy – sequence: 48 givenname: Paola surname: Cicconi fullname: Cicconi, Paola – sequence: 49 givenname: Marta surname: Boffito fullname: Boffito, Marta – sequence: 50 givenname: Ana surname: Milinkovic fullname: Milinkovic, Ana – sequence: 51 givenname: Ruth surname: Byrne fullname: Byrne, Ruth – sequence: 52 givenname: Roya surname: Movahedi fullname: Movahedi, Roya – sequence: 53 givenname: Rosalie surname: Housman fullname: Housman, Rosalie – sequence: 54 givenname: Naveed surname: Kara fullname: Kara, Naveed – sequence: 55 givenname: Ellen surname: Brown fullname: Brown, Ellen – sequence: 56 givenname: Andrea surname: Cipriani fullname: Cipriani, Andrea – sequence: 57 givenname: Mary-Jane surname: Attenburrow fullname: Attenburrow, Mary-Jane – sequence: 58 givenname: Katharine A surname: Smith fullname: Smith, Katharine A – sequence: 59 givenname: Jonathan surname: Packham fullname: Packham, Jonathan – sequence: 60 givenname: Geoff surname: Sparrow fullname: Sparrow, Geoff – sequence: 61 givenname: Richard surname: Smith fullname: Smith, Richard – sequence: 62 givenname: Josephine M surname: Rosier fullname: Rosier, Josephine M – sequence: 63 givenname: Khalid surname: Saja fullname: Saja, Khalid – sequence: 64 givenname: Nyasha surname: Nago fullname: Nago, Nyasha – sequence: 65 givenname: Brian surname: Camilleri fullname: Camilleri, Brian – sequence: 66 givenname: Anita surname: Immanuel fullname: Immanuel, Anita – sequence: 67 givenname: Mike surname: Hamblin fullname: Hamblin, Mike – sequence: 68 givenname: Rawlings surname: Osagie fullname: Osagie, Rawlings – sequence: 69 givenname: Mahalakshmi surname: Mohan fullname: Mohan, Mahalakshmi – sequence: 70 givenname: Hilary surname: Floyd fullname: Floyd, Hilary – sequence: 71 givenname: Suzanne surname: Goddard fullname: Goddard, Suzanne – sequence: 72 givenname: Sanjay surname: Mutgi fullname: Mutgi, Sanjay – sequence: 73 givenname: John surname: Evans fullname: Evans, John – sequence: 74 givenname: Sean surname: McKeon fullname: McKeon, Sean – sequence: 75 givenname: Neringa surname: Vilimiene fullname: Vilimiene, Neringa – sequence: 76 givenname: Rosavic surname: Chicano fullname: Chicano, Rosavic – sequence: 77 givenname: Rachel surname: Hayre fullname: Hayre, Rachel – sequence: 78 givenname: Alice surname: Pandaan fullname: Pandaan, Alice – sequence: 79 givenname: Catherine surname: Henshall fullname: Henshall, Catherine – sequence: 80 givenname: Sonia surname: Serrano fullname: Serrano, Sonia – sequence: 81 givenname: Andrea surname: Mazzella fullname: Mazzella, Andrea – sequence: 82 givenname: Thurkka surname: Rajeswaran fullname: Rajeswaran, Thurkka – sequence: 83 givenname: Moncy surname: Mathew fullname: Mathew, Moncy – sequence: 84 givenname: Karen surname: Bisnauthsing fullname: Bisnauthsing, Karen – sequence: 85 givenname: Laura surname: Bremner fullname: Bremner, Laura – sequence: 86 givenname: Henry surname: Fok fullname: Fok, Henry – sequence: 87 givenname: Franca surname: Morselli fullname: Morselli, Franca – sequence: 88 givenname: Paola surname: Cinardo fullname: Cinardo, Paola – sequence: 89 givenname: Blair surname: Merrick fullname: Merrick, Blair – sequence: 90 givenname: Lucy surname: Sowole fullname: Sowole, Lucy – sequence: 91 givenname: Samantha surname: Broadhead fullname: Broadhead, Samantha – sequence: 92 givenname: Natalie surname: Palmer fullname: Palmer, Natalie – sequence: 93 givenname: Jessica surname: Cordle fullname: Cordle, Jessica – sequence: 94 givenname: Jaimie Wilson surname: Goldsmith fullname: Goldsmith, Jaimie Wilson – sequence: 95 givenname: Enya surname: Cooney fullname: Cooney, Enya – sequence: 96 givenname: Beth surname: Jackson fullname: Jackson, Beth – sequence: 97 givenname: Thilina surname: Jayatilleke fullname: Jayatilleke, Thilina – sequence: 98 givenname: Zelda surname: Cheng fullname: Cheng, Zelda – sequence: 99 givenname: Toby surname: Helliwell fullname: Helliwell, Toby – sequence: 100 givenname: Adrian surname: Chudyk fullname: Chudyk, Adrian |
Copyright | Copyright © 2022 Elsevier Ltd. All rights reserved. |
Copyright_xml | – notice: Copyright © 2022 Elsevier Ltd. All rights reserved. |
CorporateAuthor | 2019nCoV-302 Study Group |
CorporateAuthor_xml | – name: 2019nCoV-302 Study Group |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1016/S2213-2600(21)00409-4 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2213-2619 |
ExternalDocumentID | 34800364 |
Genre | Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GrantInformation | Novavax. |
GrantInformation_xml | – fundername: Medical Research Council grantid: MC_UU_00004/04 – fundername: Wellcome Trust |
GroupedDBID | .1- .FO 0R~ 1P~ 4.4 457 53G AAEDT AAEDW AALRI AAMRU AAQFI AAQQT AAXUO ABJNI ACGFS ADBBV AENEX AFRHN AFTJW AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ CGR CUY CVF EBS ECM EIF EJD FDB HZ~ M41 NPM O9- OI- OU. ROL TLN Z5R |
ID | FETCH-LOGICAL-c467t-7e9a1e60cdf5b2b70a5d7b4b63b7dd7c7e316123968eff234b7b16e9f513e6b42 |
IngestDate | Sat Nov 02 12:07:55 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
License | Copyright © 2022 Elsevier Ltd. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c467t-7e9a1e60cdf5b2b70a5d7b4b63b7dd7c7e316123968eff234b7b16e9f513e6b42 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8598212 |
PMID | 34800364 |
ParticipantIDs | pubmed_primary_34800364 |
PublicationCentury | 2000 |
PublicationDate | 2022-02-01 |
PublicationDateYYYYMMDD | 2022-02-01 |
PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | The lancet respiratory medicine |
PublicationTitleAlternate | Lancet Respir Med |
PublicationYear | 2022 |
SSID | ssj0000884204 |
Score | 2.6232142 |
Snippet | The safety and immunogenicity profile of COVID-19 vaccines when administered concomitantly with seasonal influenza vaccines have not yet been reported. We... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 167 |
SubjectTerms | Adolescent Adult Aged COVID-19 COVID-19 Vaccines Double-Blind Method Humans Immunogenicity, Vaccine Influenza Vaccines - adverse effects Middle Aged SARS-CoV-2 Seasons Young Adult |
Title | Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial |
URI | https://www.ncbi.nlm.nih.gov/pubmed/34800364 |
Volume | 10 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3Nb9MwFMCtFaRpl4lvGAz5wGFTakicb26ogAbSyqFd1dtkO46oFOppK0XsH-Xf4T3badMOpMElqpzGSft-fX5-fR-EvFIVrHFFkbBMlSlLVBWzQsoag8YrWF50GtkiSafD7OQs-TxNpzu9w07U0veFfK2u_5hX8j9ShTGQK2bJ_oNkV5PCALwG-cIRJAzHW8l4JGrtivrPMM3DwBtnypf5R4e4xvoQ2M_dJkEOvkw-vWdRGSyFUt64HE6mbGAmPM7R4xoow4SvpqtXgenoRrT-wplraHIt2hlsOJ2wbQIa4_-vvwJN1BaqFgGshJUBlJxL1Uj0AetLJhus0mjHbFCYNMzHzDd-9CusrkEc2KYiXQMasW5s3nZw2YkS2A4RGIOacop-5ELWXJCRwCA2q_6X6wglg6ktS72RD9m5ojE_xM9VQHHXSwIb7HAVcaKtNuU8ihluFzdUf9hBnHf0eOR6hNxYX5yrY-Qnwz7aBYcVp0RdWLp0pQ53F98seHFSYNmfW5zdKv3dnuqRXl5gX5Khd0VZMwN-YTxM1llpb9aPdcSjY_9Ie2S3nWZr52QtqPE9su-3PvSd4_g-2dHzB2T31EvuIfnlcO7TTZj7FBiiLcrU1FTQFmXqQaRHHZCP6RbGFDGmLcZ0hXF79dVbuAXtQExbiN3d1hD36TbCfXoTYBhDfGlMLb6PyNnHD-PBCfN9R5gCs2HBcl2KSGehqupUcpmHIq1ymcgslnlV5SrXcYRVi8qsgA_P40TmMsp0WadRrDOZ8MfkztzM9VMCX44O6yirK1GDqV7D7oArmYoS9GDFdcGfkSdOJOcXrrjMeSusg7-eeU721oS_IHdr0Gb6EEzjhXxpEfkNq1-58A |
link.rule.ids | 780 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety%2C+immunogenicity%2C+and+efficacy+of+a+COVID-19+vaccine+%28NVX-CoV2373%29+co-administered+with+seasonal+influenza+vaccines%3A+an+exploratory+substudy+of+a+randomised%2C+observer-blinded%2C+placebo-controlled%2C+phase+3+trial&rft.jtitle=The+lancet+respiratory+medicine&rft.au=Toback%2C+Seth&rft.au=Galiza%2C+Eva&rft.au=Cosgrove%2C+Catherine&rft.au=Galloway%2C+James&rft.date=2022-02-01&rft.eissn=2213-2619&rft.volume=10&rft.issue=2&rft.spage=167&rft_id=info:doi/10.1016%2FS2213-2600%2821%2900409-4&rft_id=info%3Apmid%2F34800364&rft_id=info%3Apmid%2F34800364&rft.externalDocID=34800364 |